#JPM22: 4 top R&D chiefs dis­cuss the key forces re­shap­ing bio­phar­ma

On Tues­day I had a chance to sit down with 4 top R&D chiefs of some of the biggest or­ga­ni­za­tions in the in­dus­try. There’s no ques­tion that the pan­dem­ic has been re­shap­ing R&D, and I want­ed to talk about the in­ter­nal and ex­ter­nal forces they’re ex­pe­ri­enc­ing that are con­tin­u­ing to re­make our ideas about re­search and de­vel­op­ment. — John Car­roll

John Car­roll:

Okay, every­body. This is John Car­roll. I’m back. I’m the ed­i­tor of End­points News back with you with our lat­est pan­el dis­cus­sion re­lat­ed to R&D. I’ve got a great pan­el here to­day, and I re­al­ly put a lot of thought in­to who I want­ed to have on this pan­el, and I think in a lot of dif­fer­ent re­spects it’s just gold all the way through.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER